TTN and Duchenne muscular dystrophy: Regardless, additional studies of urinary titin through the natural history of DMD, as well as its performance over time in clinical trials and its ability to bolster the interpretation of both functional outcome measures and microdystrophin expression itself in therapeutic trials, may improve the ability to detect and quantify the benefits of therapeutic approaches aimed at restoring muscle integrity, such as microdystrophin gene therapy.